CRISPR Therapeutics : 20201021 CTX110 Initial Data Presentation

®

Top-Line Results from the Phase 1 CARBON Trial

of CTX110™

October 21, 2020

Forward-Looking Statements

The presentation and other related materials may contain a number of "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding CRISPR Therapeutics' expectations about any or all of the following: (i) the safety, efficacy and clinical progress of our various clinical programs; (ii) the status of clinical trials (including, without limitation, the expected timing of data releases, announcement of additional programs and activities at clinical trial sites) and expectations regarding the data that is being presented; (iii) the data that will be generated by ongoing and planned clinical trials, and the ability to use that data for the design and initiation of further clinical trials; and (iv) the therapeutic value, development, and commercial potential of CRISPR/Cas9 gene editing technologies and therapies, including as compared to other therapies. Without limiting the foregoing, the words "believes," "anticipates," "plans," "expects" and similar expressions are intended to identify forward-looking statements. You are cautioned that forward-looking statements are inherently uncertain. Although CRISPR Therapeutics believes that such statements are based on reasonable assumptions within the bounds of its knowledge of its business and operations, forward-looking statements are neither promises nor guarantees and they are necessarily subject to a high degree of uncertainty and risk. Actual performance and results may differ materially from those projected or suggested in the forward-looking statements due to various risks and uncertainties. These risks and uncertainties include, among others: the potential for initial and preliminary data from any clinical trial and initial data from a limited number of patients not to be indicative of final trial results; the potential that clinical trial results may not be favorable; potential impacts due to the coronavirus pandemic, such as the timing and progress of clinical trials; that future competitive or other market factors may adversely affect the commercial potential for CRISPR Therapeutics' product candidates; uncertainties regarding the intellectual property protection for CRISPR Therapeutics' technology and intellectual property belonging to third parties, and the outcome of proceedings (such as an interference, an opposition or a similar proceeding) involving all or any portion of such intellectual property; and those risks and uncertainties described under the heading "Risk Factors" in CRISPR Therapeutics' most recent annual report on Form 10-K, quarterly report on Form 10-Q and in any other subsequent filings made by CRISPR Therapeutics with the U.S. Securities and Exchange Commission, which are available on the SEC's website at www.sec.gov. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they are made. CRISPR Therapeutics disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this presentation, other than to the extent required by law.

CRISPR THERAPEUTICS® standard character mark and design logo, CTX001™, CTX110™, CTX120™, and CTX130™ are trademarks and registered trademarks of CRISPR Therapeutics AG. All other trademarks and registered trademarks are the property of their respective owners.

© 2020 CRISPR Therapeutics	2

Presenters on Today's Call

Samarth Kulkarni, PhD	Chief Executive Officer
CRISPR Therapeutics
Ewelina Morawa, MD	Vice President, Clinical Development
CRISPR Therapeutics
		Professor of Medicine and Division Director of Hematologic Malignancies
Joseph McGuirk, DO	and Cellular Therapeutics
		University of Kansas Medical Center
Tony Ho, MD	Executive Vice President, Head of Research & Development
CRISPR Therapeutics
© 2020 CRISPR Therapeutics	3

We Have Made Tremendous Progress Over the Past 5 Years

• Built the leading CRISPR company: 4 programs in the clinic; >300 employees; >$1B cash balance
• Demonstrated, for the first time, the power of CRISPR gene editing in rare diseases: initial data with CTX001™ supportive of a potential functional cure for sickle cell disease and beta thalassemia
• Advanced three gene-edited allogeneic CAR-T programs into the clinic across four trials
• In parallel, expanded into regenerative medicine and progressed our in vivo efforts
• Created a sustainable innovation engine with pre-eminent capabilities
• And today, we show the promise and potential of CRISPR-edited cell therapies in the fight against cancer

© 2020 CRISPR Therapeutics	4